Fundraising FoxMODULATION THERAPEUTICS, INC.
Morgantown, US · 1 known investors
Find your way into MODULATION THERAPEUTICS, INC.
Sign up to find every way you can get introduced to MODULATION THERAPEUTICS, INC.
- Your email: who you already know at MODULATION THERAPEUTICS, INC., and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the MODULATION THERAPEUTICS, INC. team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Modulation Therapeutics discovers and develops novel drug candidates targeting aggressive cancers and liver disease using peptide-based, small molecule, and targeted radio-therapy approaches. Founded in 2011 as a spinoff of Moffitt Cancer Center and now based in Morgantown, West Virginia, the company aims to advance three first-in-class therapies for nine disease indications through FDA approval.
Founders & leadership
Investors · 1
Non-dilutive funding · 17 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $1.3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2023 | $344.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $400K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2019 | $258.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $2.1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2018 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $248.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2017 | $284K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $242.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2016 | $279K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $299.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2015 | $244.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2014 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2013 | $288.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $218.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $156.2K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does MODULATION THERAPEUTICS, INC. do?
- Modulation Therapeutics discovers and develops novel drug candidates targeting aggressive cancers and liver disease using peptide-based, small molecule, and targeted radio-therapy approaches. Founded in 2011 as a spinoff of Moffitt Cancer Center and now based in Morgantown, West Virginia, the company aims to advance three first-in-class therapies for nine disease indications through FDA approval.
- Who founded MODULATION THERAPEUTICS, INC.?
- MODULATION THERAPEUTICS, INC. was founded by Lori Hazlehurst, Mark McLaughlin.
- Who are MODULATION THERAPEUTICS, INC.'s investors?
- MODULATION THERAPEUTICS, INC.'s investors include Florida Technology Seed Capital Fund.
- Where is MODULATION THERAPEUTICS, INC. headquartered?
- MODULATION THERAPEUTICS, INC. is headquartered in Morgantown, US.